...
首页> 外文期刊>Tropical Journal of Pharmaceutical Research >Effect of Shensong Yangxin on heart failure in preserved ejection fraction rat model
【24h】

Effect of Shensong Yangxin on heart failure in preserved ejection fraction rat model

机译:参松养心丸对射血分数保留模型大鼠心力衰竭的影响

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Purpose: To investigate the interventional effect of ShensongYangxin (SSYX) on heart failure (HF) using preserved ejection fraction (HFpEF) rat model. Methods: HFpEF rat model was established using abdominal aorta coarctation method and randomly divided into a positive drug control group; SSYX at high, medium, and low dosage groups; and normal control group. After 8 weeks oral treatment of SSYX, echocardiography and cardiac catheterization were used to investigate the effects of SSYX on HFpEF rat cardiac functions, including mean heart rate (HR), left ventricle anterior and posterior wall thicknesses at end diastole (LVAWd + LVPWd), left ventricular internal diameter at end diastole (LVIDd), and left ventricle mass (LVM). Results: SSYX markedly decreased heart weight and improved survival rate (p 0.01) after 12 weeks of treatment. The ex pression of NT-proBNP decreased in a dose-dependent manner and was significantly lower in SSYX treatment groups (p 0.01). Compared with normal control group, ex pression of CaMK II, PKA and RyR2 was significantly lower (p 0.005), while ex pression level of SERCA2a significantly increased after 4 g/kg/day SSYX treatment (p 0.01). Conclusion: SSYX significantly attenuates HFpEF-induced cardiac dysfunction and increases survival rate, suggesting that SSYX may prevent HF via regulation of cytoplasmic Ca 2+ handling. SSYX reduces plasma NT-proBNP levels, lending support for its therapeutic potential in HF management.
机译:目的:采用保留射血分数(HFpEF)大鼠模型研究神松养心(SSYX)对心力衰竭(HF)的干预作用。方法:采用腹主动脉缩窄法建立HFpEF大鼠模型,随机分为阳性药物对照组。高,中,低剂量组的SSYX;和正常对照组。在SSYX口服治疗8周后,使用超声心动图和心脏导管检查来研究SSYX对HFpEF大鼠心脏功能的影响,包括平均心率(HR),舒张末期左心室前后壁厚度(LVAWd + LVPWd),舒张末期的左心室内径(LVIDd)和左心室质量(LVM)。结果:治疗12周后,SSYX显着降低了心脏重量并提高了存活率(p <0.01)。 NT-proBNP的表达以剂量依赖性方式降低,在SSYX治疗组中显着降低(p <0.01)。与正常对照组相比,CaMK II,PKA和RyR2的表达显着降低(p <0.005),而在4 g / kg / day SSYX处理后SERCA2a的表达水平显着增加(p <0.01)。结论:SSYX可以显着减轻HFpEF引起的心脏功能障碍,并提高生存率,这表明SSYX可以通过调节细胞质Ca 2+的处理来预防HF。 SSYX降低血浆NT-proBNP水平,为其在HF治疗中的治疗潜力提供支持。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号